Cover Image

Discovering Severe Adverse Reactions From Pharmacokinetic Drug–Drug Interactions Through Literature Analysis and Electronic Health Record Verification

Fuente: Wiley Open Access

Saved in:

Bibliographic Details
Main Authors:	Eugene Jeong, Yu Su, Lang Li, You Chen
Format:	Artículo Open Access
Published:	Wiley 2024
Subjects:	Clinical Pharmacology & Therapeutics
Online Access:	Acceder al recurso
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

The Persistent Ambiguity of Adverse Drug Reactions
by: Edward M. Sellers, et al.
Published: (2025)

Combination Therapy With Guselkumab and Golimumab in Patients With Moderately to Severely Active Ulcerative Colitis: Pharmacokinetics, Immunogenicity and Drug–Drug Interactions
by: Jie Shao, et al.
Published: (2024)

Drug‐Event Pairs as Indicators for the Detection of Adverse Drug Reactions during Hospitalization in Routinely Collected Electronic Data Sources
by: Anna Maria Wermund, et al.
Published: (2025)

Clinical and Physiologically Based Pharmacokinetic Model Evaluations of Adagrasib Drug–Drug Interactions
by: Cornelius Cilliers, et al.
Published: (2024)

The Burden of Adverse Drug Reactions in Africa in the Context of Pharmacogenetics‐Based Clinical Guidelines
by: Janine Scholefield, et al.
Published: (2026)

Comprehensive Evaluation of OATP‐ and BCRP‐Mediated Drug–Drug Interactions of Methotrexate Using Physiologically‐Based Pharmacokinetic Modeling
by: Sejung Hwang, et al.
Published: (2024)

Application of Physiologically Based Pharmacokinetic Modeling to Inform Dose Selection of Mezigdomide in a Phase I Drug–Drug Interaction Study
by: Joseph Burnett, et al.
Published: (2025)

Zibotentan Can Be Co‐administered with Contraceptives Containing Ethinyl Estradiol and Levonorgestrel: A Pharmacokinetic Drug–Drug Interaction Study
by: Anne‐Kristina Mercier, et al.
Published: (2024)

Cutaneous Adverse Drug Reactions Associated With BRAF and MEK Inhibitors: A Real‐World Analysis of WHO Pharmacovigilance Data
by: Natalia Sauer, et al.
Published: (2026)

Effects of GLPG3970 on Sulfasalazine and Methotrexate Pharmacokinetics in Healthy Adults: Two Open‐Label, Phase I, Drug–Drug Interaction Studies
by: Mariska van der Plas, et al.
Published: (2024)

Phenotypic Models of Drug–Drug‐Gene Interactions Mediated by Cytochrome Drug‐Metabolizing Enzymes
by: Roberto Viviani, et al.
Published: (2024)

Drug Interactions Brewing
by: Matthijs W. van Hoogdalem, et al.
Published: (2025)

Physiologically Based Pharmacokinetic Modeling to Investigate the Disease‐Drug–Drug Interactions between Voriconazole and Nirmatrelvir/Ritonavir in COVID‐19 Patients with CYP2C19 Phenotypes
by: Peile Wang, et al.
Published: (2024)

Mechanistic Determinants of Daprodustat Drug–Drug Interactions and Pharmacokinetics in Hepatic Dysfunction and Chronic Kidney Disease: Significance of OATP1B‐CYP2C8 Interplay
by: Yi‐An Bi, et al.
Published: (2024)

Strategy for Identifying Rational Sensitivity Analysis Using PBPK Modeling for Precipitant Drug–Drug Interaction Predictions
by: Kunal S. Taskar, et al.
Published: (2025)

Clinical Evaluation of Drug–Drug Interactions with Obeldesivir, an Orally Administered Antiviral Agent
by: Chi‐Chi Peng, et al.
Published: (2025)

Information Bias in Electronic Health Records and Administrative Claims Data: A Targeted Review of the Recent Literature
by: Patrick J. Arena, et al.
Published: (2025)

A Comprehensive CYP2D6 Drug–Drug–Gene Interaction Network for Application in Precision Dosing and Drug Development
by: Simeon Rüdesheim, et al.
Published: (2025)

Chat GPT and the Challenges to Detect Potential Drug–Drug Interactions Related to QT Prolongation
by: Emanuel Raschi, et al.
Published: (2025)

Thinking Three‐Dimensionally: A Self‐ and Externally‐Controlled Approach to Screening for Drug–Drug–Drug Interactions Among High‐Risk Populations
by: Emily K. Acton, et al.
Published: (2024)

Identifying Drug–Drug Interactions in Spontaneous Reports Utilizing Signal Detection and Biological Plausibility Aspects
by: Elpida Kontsioti, et al.
Published: (2024)

Phenoconversion Due to Drug–Drug Interactions in CYP2C19 Genotyped Healthy Volunteers
by: Kenza Abouir, et al.
Published: (2024)

Population Pharmacokinetic Modeling and Exposure–Response Analysis for the Antibody–Drug Conjugate Enfortumab Vedotin in Locally Advanced or Metastatic Urothelial Carcinoma
by: Peiying Zuo, et al.
Published: (2024)

Drug–Drug Interaction Between Dihydroartemisinin–Piperaquine and Sulfadoxine‐Pyrimethamine During Malaria Chemoprevention in Pregnant Women
by: Norah Mwebaza, et al.
Published: (2024)

Prediction of Local Drug Exposure of Dry Powder Inhaler CXG87 (budesonide/formoterol) Using Physiologically‐Based Pharmacokinetic Model
by: Yuran Cao, et al.
Published: (2025)

The US Food and Drug Administration's Model‐Informed Drug Development Meeting Program: From Pilot to Pathway
by: Rajanikanth Madabushi, et al.
Published: (2024)

New Biomarkers for Renal Transporter‐Mediated Drug–Drug Interactions: Metabolomic Effects of Cimetidine, Probenecid, Verapamil, and Rifampin in Humans
by: Arne Gessner, et al.
Published: (2024)

Drug Loss in Japan: A Comparative Analysis with Europe for New Drugs Developed by Emerging Biopharma Companies
by: Mihoko Kobayashi, et al.
Published: (2025)

The Impact of QT‐Prolonging Medications and Drug–Drug Interactions on QTc Interval Prolongation in Hospitalized Patients: A Case‐Crossover Study
by: Hsiu‐Ting Chien, et al.
Published: (2024)

Predictive Modeling of Drug‐Related Adverse Events with Real‐World Data: A Case Study of Linezolid Hematologic Outcomes
by: Anu Patel, et al.
Published: (2024)

Biomarker‐Based Prediction of OATP1B1 Activity in Clinical Routine—Investigating Coproporphyrins as Markers for Drug–Drug–Gene Interactions
by: Leila Potzel, et al.
Published: (2026)

Therapeutic Drug Monitoring of Oral Oncology Drugs: Finding the Right Nails
by: Niels A. D. Guchelaar, et al.
Published: (2024)

Drug‐Induced Acute Pancreatitis: A Real‐World Pharmacovigilance Study Using the FDA Adverse Event Reporting System Database
by: Dongxuan Li, et al.
Published: (2024)

Analysis of Real‐World Data Utilization in the Orphan Drug Approval Process: Focusing on New Drug Marketing Applications Submitted to the FDA
by: Minji Kim, et al.
Published: (2026)

Effects of Cimetidine and Dolutegravir on the Endogenous Drug–Drug Interaction Biomarkers for Organic Cation Transporter 2 and Multidrug and Toxin Extrusion Protein 1 in Healthy Volunteers
by: Tomoki Koishikawa, et al.
Published: (2024)

Gut Microbiota in Patients with Tuberculosis Associated with Different Drug Exposures of Antituberculosis Drugs
by: Yue Zhu, et al.
Published: (2025)

New Horizons of Model Informed Drug Development in Rare Diseases Drug Development
by: Amitava Mitra, et al.
Published: (2024)

Therapeutic Drug Monitoring of Oral Oncology Drugs: Another Example of Maslow's Hammer
by: Mark J. Ratain
Published: (2024)

Assessment of Efficacy Evidence for Approvals of Novel Drugs in China Between 2018 and 2022
by: Yang Xu, et al.
Published: (2024)

Population‐Based Validation Results From the Drug Repurposing for Effective Alzheimer's Medicines (DREAM) Study
by: Rishi J. Desai, et al.
Published: (2025)